We're moving toward precision medicine and personalized treatment. The objective is to overcome resistance and come up with treatment plans that address the underlying disease biology and take personal factors about the patients into consideration. This is important for us to understand MCL individually. We are moving toward doing more sequencing analyses or targeted mutation analysis at dedicated centers that are doing those assays. They would provide information on critical gene mutations such as TP53, which could be associated with an aggressive type of disease course that may not respond well to chemotherapy or specific biological agents.
... to read the full story